Background The precise regulation and maintenance of balance between cell proliferation, differentiation and death in metazoan are critical for tissue homeostasis. CCAAT/enhancer-binding protein alpha (C/EBPα) has been implicated as a key regulator of differentiation and proliferation in various cell types. Here we investigated the potential dynamic change and role of C/EBPα protein during apoptosis induction. Methodology/Principal Findings Upon onset of apoptosis induced by various kinds of inducers such as NSC606985, etoposide and others, C/EBPα expression presented a profound down-regulation in leukemic cell lines and primary cells via induction of protein degradation and inhibition of transcription, as assessed respectively by cycloheximide inhibition test, real-time quantitative RT-PCR and luciferase reporter assay. Applying chemical inhibition, forced expression of dominant negative mutant and catalytic fragment (CF) of protein kinase Cdelta (PKCδ), which was proteolytically activated during apoptosis induction tested, we showed that the active PKCδ protein contributed to the increased degradation of C/EBPα protein. Three specific proteasome inhibitors antagonized C/EBPα degradation during apoptosis induction. More importantly, ectopic expression of PKCδ-CF stimulated the ubiquitination of C/EBPα protein, while the chemical inhibition of PKCδ action significantly inhibited the enhanced ubiquitination of C/EBPα protein under NSC606985 treatment. Additionally, silencing of C/EBPα expression by small interfering RNAs enhanced, while inducible expression of C/EBPα inhibited NSC606985/etoposide-induced apoptosis in leukemic cells. Conclusions/Significance These observations indicate that the activation of PKCδ upon apoptosis results in the increased proteasome-dependent degradation of C/EBPα, which partially contributes to PKCδ-mediated apoptosis.
References
[1]
Droin N, Cathelin S, Jacquel A, Guery L, Garrido C, et al. (2008) A role for caspases in the differentiation of erythroid cells and macrophages. Biochimie 90: 416–422.
[2]
Lu QL, Abel P, Foster CS, Lalani EN (1996) bcl-2: role in epithelial differentiation and oncogenesis. Hum Pathol 27: 102–110.
[3]
Zhang DE, Zhang P, Wang ND, Hetherington CJ, Darlington GJ, et al. (1997) Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. Proc Natl Acad Sci U S A 94: 569–574.
[4]
Radomska HS, Huettner CS, Zhang P, Cheng T, Scadden DT, et al. (1998) CCAAT/enhancer binding protein alpha is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors. Mol Cell Biol 18: 4301–4314.
[5]
Schuster MB, Porse BT (2006) C/EBPalpha: a tumour suppressor in multiple tissues? Biochim Biophys Acta 1766: 88–103.
[6]
Nerlov C (2004) C/EBPalpha mutations in acute myeloid leukaemias. Nat Rev Cancer 4: 394–400.
[7]
Pabst T, Mueller BU, Harakawa N, Schoch C, Haferlach T, et al. (2001) AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat Med 7: 444–451.
[8]
Westendorf JJ, Yamamoto CM, Lenny N, Downing JR, Selsted ME, et al. (1998) The t(8;21) fusion product, AML-1-ETO, associates with C/EBP-alpha, inhibits C/EBP-alpha-dependent transcription, and blocks granulocytic differentiation. Mol Cell Biol 18: 322–333.
[9]
Emoto Y, Kisaki H, Manome Y, Kharbanda S, Kufe D (1996) Activation of protein kinase Cdelta in human myeloid leukemia cells treated with 1-beta-D-arabinofuranosylcytosine. Blood 87: 1990–1996.
[10]
Perrotti D, Cesi V, Trotta R, Guerzoni C, Santilli G, et al. (2002) BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2. Nat Genet 30: 48–58.
[11]
Paz-Priel I, Cai DH, Wang D, Kowalski J, Blackford A, et al. (2005) CCAAT/enhancer binding protein alpha (C/EBPalpha) and C/EBPalpha myeloid oncoproteins induce bcl-2 via interaction of their basic regions with nuclear factor-kappaB p50. Mol Cancer Res 3: 585–596.
[12]
Rapisarda A, Uranchimeg B, Scudiero DA, Selby M, Sausville EA, et al. (2002) Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res 62: 4316–4324.
[13]
Liu W, Zhu YS, Guo M, Yu Y, Chen GQ (2007) Therapeutic efficacy of NSC606985, a novel camptothecin analog, in a mouse model of acute promyelocytic leukemia. Leuk Res 31: 1565–1574.
[14]
Song MG, Gao SM, Du KM, Xu M, Yu Y, et al. (2005) Nanomolar concentration of NSC606985, a camptothecin analog, induces leukemic-cell apoptosis through protein kinase Cdelta-dependent mechanisms. Blood 105: 3714–3721.
[15]
Porter AG, Janicke RU (1999) Emerging roles of caspase-3 in apoptosis. Cell Death Differ 6: 99–104.
[16]
Ramji DP, Foka P (2002) CCAAT/enhancer-binding proteins: structure, function and regulation. Biochem J 365: 561–575.
[17]
Brodie C, Blumberg PM (2003) Regulation of cell apoptosis by protein kinase c delta. Apoptosis 8: 19–27.
[18]
Basu A (2003) Involvement of protein kinase C-delta in DNA damage-induced apoptosis. J Cell Mol Med 7: 341–350.
[19]
Emoto Y, Manome Y, Meinhardt G, Kisaki H, Kharbanda S, et al. (1995) Proteolytic activation of protein kinase C delta by an ICE-like protease in apoptotic cells. Embo J 14: 6148–6156.
[20]
Reyland ME, Anderson SM, Matassa AA, Barzen KA, Quissell DO (1999) Protein kinase C delta is essential for etoposide-induced apoptosis in salivary gland acinar cells. J Biol Chem 274: 19115–19123.
[21]
Yu Y, Wang LS, Shen SM, Xia L, Zhang L, et al. (2007) Subcellular proteome analysis of camptothecin analogue NSC606985-treated acute myeloid leukemic cells. J Proteome Res 6: 3808–3818.
[22]
Sitailo LA, Tibudan SS, Denning MF (2006) The protein kinase C delta catalytic fragment targets Mcl-1 for degradation to trigger apoptosis. J Biol Chem 281: 29703–29710.
[23]
Soltoff SP (2007) Rottlerin: an inappropriate and ineffective inhibitor of PKCdelta. Trends Pharmacol Sci 28: 453–458.
[24]
Leitges M, Elis W, Gimborn K, Huber M (2001) Rottlerin-independent attenuation of pervanadate-induced tyrosine phosphorylation events by protein kinase C-delta in hemopoietic cells. Lab Invest 81: 1087–1095.
[25]
Page K, Li J, Zhou L, Iasvovskaia S, Corbit KC, et al. (2003) Regulation of airway epithelial cell NF-kappa B-dependent gene expression by protein kinase C delta. J Immunol 170: 5681–5689.
[26]
Matassa AA, Carpenter L, Biden TJ, Humphries MJ, Reyland ME (2001) PKCdelta is required for mitochondrial-dependent apoptosis in salivary epithelial cells. J Biol Chem 276: 29719–29728.
[27]
Boer J, Bonten-Surtel J, Grosveld G (1998) Overexpression of the nucleoporin CAN/NUP214 induces growth arrest, nucleocytoplasmic transport defects, and apoptosis. Mol Cell Biol 18: 1236–1247.
[28]
Fischer U, Janicke RU, Schulze-Osthoff K (2003) Many cuts to ruin: a comprehensive update of caspase substrates. Cell Death Differ 10: 76–100.
[29]
Wang L, Zhao WL, Yan JS, Liu P, Sun HP, et al. (2007) Eriocalyxin B induces apoptosis of t(8;21) leukemia cells through NF-kappaB and MAPK signaling pathways and triggers degradation of AML1-ETO oncoprotein in a caspase-3-dependent manner. Cell Death Differ 14: 306–317.
[30]
Lu Y, Peng ZG, Yuan TT, Yin QQ, Xia L, et al. (2008) Multi-sites cleavage of leukemogenic AML1-ETO fusion protein by caspase-3 and its contribution to increased apoptotic sensitivity. Leukemia 22: 378–386.
[31]
Shim M, Smart RC (2003) Lithium stabilizes the CCAAT/enhancer-binding protein alpha (C/EBPalpha) through a glycogen synthase kinase 3 (GSK3)-independent pathway involving direct inhibition of proteasomal activity. J Biol Chem 278: 19674–19681.
[32]
Meng L, Mohan R, Kwok BH, Elofsson M, Sin N, et al. (1999) Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci U S A 96: 10403–10408.
[33]
Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, et al. (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59: 2615–2622.
[34]
Lin KI, Baraban JM, Ratan RR (1998) Inhibition versus induction of apoptosis by proteasome inhibitors depends on concentration. Cell Death Differ 5: 577–583.
[35]
Voorhees PM, Dees EC, O'Neil B, Orlowski RZ (2003) The proteasome as a target for cancer therapy. Clin Cancer Res 9: 6316–6325.
[36]
Yoon K, Smart RC (2004) C/EBPalpha is a DNA damage-inducible p53-regulated mediator of the G1 checkpoint in keratinocytes. Mol Cell Biol 24: 10650–10660.
[37]
Ghayur T, Hugunin M, Talanian RV, Ratnofsky S, Quinlan C, et al. (1996) Proteolytic activation of protein kinase C delta by an ICE/CED 3-like protease induces characteristics of apoptosis. J Exp Med 184: 2399–2404.
[38]
Basu A, Akkaraju GR (1999) Regulation of caspase activation and cis-diamminedichloroplatinum(II)-induced cell death by protein kinase C. Biochemistry 38: 4245–4251.
[39]
Zheng Y, Wang LS, Xia L, Han YH, Liao SH, et al. (2009) NDRG1 is down-regulated in the early apoptotic event induced by camptothecin analogs: the potential role in proteolytic activation of PKC delta and apoptosis. Proteomics 9: 2064–2075.
[40]
Basu A, Woolard MD, Johnson CL (2001) Involvement of protein kinase C-delta in DNA damage-induced apoptosis. Cell Death Differ 8: 899–908.
[41]
Yoshida K (2007) PKCdelta signaling: mechanisms of DNA damage response and apoptosis. Cell Signal 19: 892–901.
[42]
Cross T, Griffiths G, Deacon E, Sallis R, Gough M, et al. (2000) PKC-delta is an apoptotic lamin kinase. Oncogene 19: 2331–2337.
[43]
Leverrier S, Vallentin A, Joubert D (2002) Positive feedback of protein kinase C proteolytic activation during apoptosis. Biochem J 368: 905–913.
[44]
Bharti A, Kraeft SK, Gounder M, Pandey P, Jin S, et al. (1998) Inactivation of DNA-dependent protein kinase by protein kinase Cdelta: implications for apoptosis. Mol Cell Biol 18: 6719–6728.
[45]
Ren J, Datta R, Shioya H, Li Y, Oki E, et al. (2002) p73beta is regulated by protein kinase Cdelta catalytic fragment generated in the apoptotic response to DNA damage. J Biol Chem 277: 33758–33765.
[46]
Liu J, Chen J, Dai Q, Lee RM (2003) Phospholipid scramblase 3 is the mitochondrial target of protein kinase C delta-induced apoptosis. Cancer Res 63: 1153–1156.
[47]
Park R, Baines JD (2006) Herpes simplex virus type 1 infection induces activation and recruitment of protein kinase C to the nuclear membrane and increased phosphorylation of lamin B. J Virol 80: 494–504.
[48]
Iturrioz X, Durgan J, Calleja V, Larijani B, Okuda H, et al. (2006) The von Hippel-Lindau tumour-suppressor protein interaction with protein kinase Cdelta. Biochem J 397: 109–120.
[49]
Walker JL, Castagnino P, Chung BM, Kazanietz MG, Assoian RK (2006) Post-transcriptional destabilization of p21cip1 by protein kinase C in fibroblasts. J Biol Chem 281: 38127–38132.
[50]
Choi BH, Hur EM, Lee JH, Jun DJ, Kim KT (2006) Protein kinase Cdelta-mediated proteasomal degradation of MAP kinase phosphatase-1 contributes to glutamate-induced neuronal cell death. J Cell Sci 119: 1329–1340.
[51]
Tang QQ, Jiang MS, Lane MD (1999) Repressive effect of Sp1 on the C/EBPalpha gene promoter: role in adipocyte differentiation. Mol Cell Biol 19: 4855–4865.
[52]
Jiang MS, Tang QQ, McLenithan J, Geiman D, Shillinglaw W, et al. (1998) Derepression of the C/EBPalpha gene during adipogenesis: identification of AP-2alpha as a repressor. Proc Natl Acad Sci U S A 95: 3467–3471.
[53]
Legraverend C, Antonson P, Flodby P, Xanthopoulos KG (1993) High level activity of the mouse CCAAT/enhancer binding protein (C/EBP alpha) gene promoter involves autoregulation and several ubiquitous transcription factors. Nucleic Acids Res 21: 1735–1742.
[54]
Kockar FT, Foka P, Hughes TR, Kousteni S, Ramji DP (2001) Analysis of the Xenopus laevis CCAAT-enhancer binding protein alpha gene promoter demonstrates species-specific differences in the mechanisms for both auto-activation and regulation by Sp1. Nucleic Acids Res 29: 362–372.
[55]
Hamada M, Sumi T, Iwai S, Nakazawa M, Yura Y (2006) Induction of endonuclease G-mediated apopotosis in human oral squamous cell carcinoma cells by protein kinase C inhibitor safingol. Apoptosis 11: 47–56.
[56]
Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi F, et al. (1991) NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 77: 1080–1086.
[57]
Lu Y, Xu YB, Yuan TT, Song MG, Lubbert M, et al. (2006) Inducible expression of AML1-ETO fusion protein endows leukemic cells with susceptibility to extrinsic and intrinsic apoptosis. Leukemia 20: 987–993.
[58]
Lee KK, Ohyama T, Yajima N, Tsubuki S, Yonehara S (2001) MST, a physiological caspase substrate, highly sensitizes apoptosis both upstream and downstream of caspase activation. J Biol Chem 276: 19276–19285.
[59]
Xu HM, Liao B, Zhang QJ, Wang BB, Li H, et al. (2004) Wwp2, an E3 ubiquitin ligase that targets transcription factor Oct-4 for ubiquitination. J Biol Chem 279: 23495–23503.
[60]
Soh JW, Weinstein IB (2003) Roles of specific isoforms of protein kinase C in the transcriptional control of cyclin D1 and related genes. J Biol Chem 278: 34709–34716.
[61]
Zhao KW, Li X, Zhao Q, Huang Y, Li D, et al. (2004) Protein kinase Cdelta mediates retinoic acid and phorbol myristate acetate-induced phospholipid scramblase 1 gene expression: its role in leukemic cell differentiation. Blood 104: 3731–3738.
